 |
|
|
| |
HBV DNA and Clinical Characteristics of Patients Who Developed HCC While Receiving Tenofovir Disoproxil Fumarate Following 8 Years of Therapy
|
| |
| |
Reported by Jules Levin
APASL 2015
March 12-15, Istanbul, Turkey
Selim Gurel1, Patrick Marcellin2, Rohit Loomba3, Thomas Berg4, Raul Aguilar Schall5, Leland J. Yee5, Phillip Dinh5, John F. Flaherty5, Eduardo B. Martins5,
Terry Therneau6, Ira Jacobson7, Scott Fung8, Maria Buti9, W. Ray Kim10
1University of Uludag, Bursa, Turkey; 2H™pital Beaujon, University Paris-Diderot and INSERM CRI/UMR
1149, Viral Hepatitis Research Centre, Clichy, France; 3University of California at San Diego, La Jolla, CA, USA; 4UniversitŠtsklinikum Leipzig, Germany; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Mayo Clinic, Rochester, MN, USA; 7Weill Cornell Medical College, New York, NY, USA; 8University of Toronto,
Toronto, Ontario, Canada; 9Hospital General Universitari Vall dÕHebron and Ciberehd del Instituto Carlos III, Barcelona, Spain; 10Stanford University School of Medicine, Palo Alto, CA, USA
|
| |
|
|
|
|
|
